Details of the Drug Reposition

General Information of This Drug (ID: DMU9C8F)

Drug Name
Bavencio   DMU9C8F
Drug Type
Monoclonal antibody

Information on Drug Reposition of This Drug

Molecular Interaction Atlas (MIA)
1 Approved Indication(s)
Indication Name Indication ID ICD-11 Status REF
Merkel cell carcinoma DISDJJ4U 2C34 Approved [1]
------------------------------------------------------------------------------------
4 Phase 3 Indication(s)
Indication Name Indication ID ICD-11 Status REF
Gastric adenocarcinoma DISWWLTC 2B72 Phase 3 [2]
Colon cancer DISVC52G 2B90.Z Phase 3 [3]
Urothelial carcinoma DISRTNTN 2C92.0 Phase 3 [2]
Head and neck cancer DISBPSQZ 2D42 Phase 3 [2]
------------------------------------------------------------------------------------
4 Phase 2 Indication(s)
Indication Name Indication ID ICD-11 Status REF
Squamous cell carcinoma DISQVIFL 2B60-2D01 Phase 2 [2]
Melanoma DIS1RRCY 2C30 Phase 2 [4]
Breast cancer DIS7DPX1 2C60-2C65 Phase 2 [2]
Testicular cancer DIS6HNYO 2C80 Phase 2 [5]
------------------------------------------------------------------------------------
1 Phase 1 Indication(s)
Indication Name Indication ID ICD-11 Status REF
Haematological malignancy DISCDP7W 2B33.Y Phase 1 [2]
------------------------------------------------------------------------------------

References

1 Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health Human Services. 2019
2 Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
3 ClinicalTrials.gov (NCT03827044) Avelumab Plus 5-FU Based Chemotherapy as Adjuvant Treatment for Stage 3 MSI-High or POLE Mutant Colon Cancer (POLEM). U.S. National Institutes of Health.
4 Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
5 ClinicalTrials.gov (NCT03403777) Avelumab in Refractory Testicular Germ Cell Cancer.. U.S. National Institutes of Health.